About: bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Sector: Healthcare
Industry: Diagnostics & Research
Latest price: $2.80 (-11.67%)
BIAF NASDAQ bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. share price
Atividade de preço de BIAF
Último preço
$ 2,800
Variação (24h)
-0,37 USD (11,67%)
Volume
124.59K
Volume (média 4 sem.)
-
Abertura
$ 3,17
Variação do dia
$ 2,80 - $ 3,27
Fechamento anterior
$ 3,17
Último negócio
23 Oct, 8:28 pm GMT+0
Atrasado
23 Oct, 8:28 pm GMT+0
BIAF price performance
Atrasado
23 Oct, 8:28 pm GMT+0
quote.marketSignals